Mumbai, Mar 07, 2015 – CPhI which hosts a number of successful and well respected pharmaceutical conferences are conducting their 4th Annual Global Pharma Regulatory Summit, 22-23-24 April 2015 at The Lalit in Mumbai. The summit will focus on the new and updated guidelines introduced by the prominent regulatory bodies around the globe.
Some of the important topics being discussed at the summit include
- Quality Based Review CMC Evaluations of ANDAs
- Expectation of USFDA towards ICH M7- Genotoxic impurities
- ICH Q9- Quality risk management
- ASEAN, MENA, Philippines, Srilanka, China – Regulatory issues and entry challenges
The summit has already attracted more than 100 delegates from companies like Cipla, Daewoong Pharmaceutical, Aptar Pharma, Famy Care, UCB, Perrigo Laboratories, Deccan Nutraceuticals, Amdipharm, Mercury Services, Sun Pharma, Jay Chemicals, Biocon, Watson Pharma, Amneal Pharma, Torrent Pharmaceuticals, J B Chemicals & Pharmaceuticals, Mankind, Intas Pharmaceuticals, Granules India, Tevapharm India, Zydus Cadila, Macleods and many more.
Post Show Report: http://ubm.io/1DNsAI0 | Brochure: http://ubm.io/1Nbff1M
Pharma Experts:
- Frances M. Zipp, President, Lachman Consultants
- Steve Richardson, Senior Regulatory Consultant, Lachman Consultants
- Paul Fleming, (Former MHRA)
- Dr. Priya Chaterjee, Director- regulatory Affairs, Merck Serono
- KS Babu, Head Regulatory, Hospira
- Nagendra Irukulapati, Head Regulatory – Emerging Markets, Aurbindo Pharma
- Arun Mishra, Head – Regulatory affairs, Abott
For further information about the summit you can contact
Mr. Mustafa Nalwalla, Marketing Manager, UBM India – Conferences
T: +91 (022) 6172 7067| E: Mustafa.nalwalla@ubm.com | W: www.pharmaregulation-india.com
CCI Newswire
